Komori
Other Disclosures4891TMS Co.,Ltd.Pharmaceuticals

Notice of publication of a paper on the renoprotective effects of an SMTP compound against acute kidney injury

Research conducted jointly by the Company and Showa Medical University, which found that SMTP-44D reduced renal dysfunction, inflammation and oxidative stress in a mouse model of ischemia-reperfusion-induced acute kidney injury, has been published in an international academic journal.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

SMTP-44D
Applicable field (uses covered by this announcement)

Acute kidney injury (AKI), ischemia-reperfusion injury, renoprotection

What the company reported numerically
Quantitative Effects

Renal function indicators, including blood urea nitrogen, serum creatinine and fractional sodium excretion, improved. NGAL, KIM-1, TNF-α, IL-1β and NOX-1 were significantly reduced or suppressed.

Relationship between the counterparty and the company
TMS Co.,Ltd.4891
Relationship with the Company

Joint research. TMS Co.,Ltd. is listed as one of the authors’ affiliations.

CounterpartyShowa Medical University

A university with a Graduate School of Pharmaceutical Sciences and a Center for Pharmacological Sciences. Other information, including its location, representative, capital and year established, is not disclosed.

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Paper published in International Journal of Molecular Sciences, DOI: https://doi.org/10.3390/ijms27198506

Announced details
ItemDetails
Names of Products / Services CoveredSMTP-44D
CounterpartyShowa Medical University
Counterparty overviewA university with a Graduate School of Pharmaceutical Sciences and a Center for Pharmacological Sciences. Other information, including its location, representative, capital and year established, is not disclosed.
Relationship with the CompanyJoint research. TMS Co.,Ltd. is listed as one of the authors’ affiliations.
Applicable areaAcute kidney injury (AKI), ischemia-reperfusion injury, renoprotection
Quantitative EffectsRenal function indicators, including blood urea nitrogen, serum creatinine and fractional sodium excretion, improved. NGAL, KIM-1, TNF-α, IL-1β and NOX-1 were significantly reduced or suppressed.
SourcePaper published in International Journal of Molecular Sciences, DOI: https://doi.org/10.3390/ijms27198506
Items this document does not state (11)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because research findings on SMTP-44D were published in the international academic journal "International Journal of Molecular Sciences."

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of publication of a paper on the renoprotective effects of an SMTP compound against acute kidney injury | TMS Co.,Ltd. (4891) timely disclosure | Komori